Glycorex Transplantation AB (publ)

DB:O33 Stock Report

Market Cap: €19.6m

Glycorex Transplantation Valuation

Is O33 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Share Price vs Fair Value

What is the Fair Price of O33 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for O33?

Key metric:

The above table shows the Price to Sales ratio for O33. This is calculated by dividing O33's market cap by their current revenue.
What is O33's PS Ratio?
PS Ratio6.9x
SalesSEK 32.32m
Market CapSEK 224.52m

Price to Sales Ratio vs Peers

How does O33's PS Ratio compare to its peers?

The above table shows the PS ratio for O33 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.9x
GME Geratherm Medical
1.1x1.9%€19.6m
PUS PULSION Medical Systems
3.7xn/a€133.6m
NN6 NanoRepro
5xn/a€17.8m
SBS Stratec
1.6x6.1%€420.0m
O33 Glycorex Transplantation
6.9xn/a€224.5m

Price to Sales Ratio vs Industry

How does O33's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.3x3.3%US$1.01b
PHH2 Paul Hartmann
0.3xn/aUS$832.18m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
O33 6.9xIndustry Avg. 4.2xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price to Sales Ratio vs Fair Ratio

What is O33's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

O33 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.9x
Fair PS Ration/a

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/23 20:21
End of Day Share Price 2025/01/22 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Glycorex Transplantation AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution